SAN DIEGO, Dec. 19 /PRNewswire/ -- Alanex Corporation announced the
addition to its Board of Directors, of Timothy J. Rink, M.A., M.D., Sc.D.
Dr. Rink is a founder of Aurora Biosciences, an ultra-high throughput
screening technology company. Dr. Rink joined the company as Chairman, CEO,
and President in February, 1996. From 1990 to 1995, Dr. Rink was President
and Chief Technical Officer of Amylin Pharmaceuticals where he was
instrumental in growing the company from a start-up to over 170 employees
while advancing three compounds into clinical development during this time.
Prior to Amylin, Dr. Rink was Vice President of Research at SmithKline Beecham
Pharmaceuticals. Dr. Rink is on the Board of Directors of CoCensys, Inc., NPS
Pharmaceuticals, Inc., Gryphon Sciences and Ciphergen Systems, Inc.
"We are very excited about adding to our Board of Directors someone with
Dr. Rink's drug discovery experience in both big pharma and biotechnology and
of building and expanding biotechnology companies. Dr. Rink has the ideal
background and experience to help guide Alanex during our future growth," said
Dr. Marvin Brown, President and CEO of Alanex.
Alanex Corporation, based in San Diego, California, is a privately held
drug discovery company whose mission is to identify small molecule drugs using
its proprietary drug discovery technologies. Alanex has developed and
integrated its combinatorial chemistry with computational chemistry, high
throughput screening and medicinal chemistry in order to accelerate the
process of going from lead generation to drug candidate. In December, 1994,
Alanex formed a strategic collaboration with Astra Pharma Inc. to discover and
develop drugs for a novel opiod receptor. In April, 1996, Alanex announced
the signing of a collaboration with Novo Nordisk related to the discovery of
small molecules for the treatment of diabetes. In July, 1996, Alanex entered
into a collaboration with Roche Bioscience, a wholly owned subsidiary of Roche
Holdings, Ltd., to discover novel small molecule drugs in the area of pain
management. In November, 1996, Alanex announced a collaboration with Aurora
Biosciences whereby Alanex will provide its exploratory chemical library for
new lead generation in Aurora's novel fluorescence screening systems.
SOURCE Alanex Corp.
 back to top
CONTACT:
Ed Baracchini, Ph.D, M.B.A., Director of
Business Development & Strategic Planning of Alanex,
619-455-3257, or eb@alanex.com
|
